AstraZeneca starts Phase 3 trial of elecoglipron against oral semaglutide
The open-label Eluminate-2 study enrolls adults with type 2 diabetes and increased cardiovascular risk who are inadequately managed on current therapy.
PR
By Priya Raman · Science Reporter
Oct 22 08:00 ETSource: ClinicalTrials.gov
The wire
- 01AstraZeneca registered NCT07662213, a randomized, open-label Phase 3 study comparing elecoglipron with oral semaglutide in adults with type 2 diabetes, with a start date of 6 July 2026.
- 02A head-to-head against oral semaglutide sets a direct efficacy, safety and tolerability benchmark in the oral incretin field rather than a placebo comparison.
- 03The trial is recruiting and no results are available; the open-label design and sponsor-run comparison are limitations to hold on to.
From the source
Read at clinicaltrials.govA Study to Find Out if the Study Drug Elecoglipron Helps Adults With Type 2 Diabetes Mellitus by Comparing it With Semaglutide, a Medicine Already Used to Treat Type 2 Diabetes Mellitus
NCT07662213 · PHASE3 · RECRUITING · Sponsor: AstraZeneca · Conditions: Type 2 Diabetes Mellitus.
Source URL https://clinicaltrials.gov/study/NCT07662213
